Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Candel Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −4 vs. Q3 2022
- Shares held
- 5.42M
- −660.5K (−10.9%) vs. Q3 2022
- Total value
- $9.70M
- −$9.40M (−49.2%) vs. Q3 2022
- New holders
- 2
- 5 more added
- Sold out
- 6
- 6 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CADL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $518.9M |
| Q1 2026 | 114 | $212.9M |
| Q4 2025 | 84 | $133.5M |
| Q3 2025 | 81 | $115.6M |
| Q2 2025 | 78 | $116.6M |
| Q1 2025 | 82 | $119.7M |
| Q4 2024 | 71 | $155.7M |
| Q3 2024 | 52 | $46.4M |
| Q2 2024 | 45 | $37.0M |
| Q1 2024 | 20 | $5.97M |
| Q4 2023 | 22 | $5.92M |
| Q3 2023 | 20 | $4.86M |
| Q2 2023 | 20 | $6.77M |
| Q1 2023 | 21 | $7.44M |
| Q4 2022 | 21 | $9.70M |
| Q3 2022 | 25 | $19.1M |
| Q2 2022 | 23 | $20.6M |
| Q1 2022 | 23 | $34.0M |
| Q4 2021 | 20 | $54.4M |
| Q3 2021 | 12 | $52.9M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Candel Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 186 | $0 | 0.00% | −1,272−87.2% | Reduced |
| Bank of America Corp | 22 | $40 | 0.00% | −184−89.3% | Reduced |
| Morgan Stanley | 92 | $165 | 0.00% | −5,188−98.3% | Reduced |
| Wells Fargo & Company | 98 | $175 | 0.00% | +2+2.1% | Added |
| Quent Capital, LLC | 182 | $326 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 352 | $630 | 0.00% | +17+5.1% | Added |
| UBS Group AG | 795 | $1.42K | 0.00% | −3,386−81.0% | Reduced |
| Tower Research Capital LLC (TRC) | 7,214 | $13.0K | 0.00% | +3,077+74.4% | Added |
| Empirical Asset Management, LLC | 12,000 | $21.5K | 0.02% | 00.0% | Unchanged |
| Jane Street Group, LLC | 13,425 | $24.0K | 0.00% | +13,425 | New |
| Northern Trust Corp | 14,483 | $25.9K | 0.00% | 00.0% | Unchanged |
| Ergoteles LLC | 26,114 | $46.7K | 0.00% | +26,114 | New |
| State Street Corp | 27,600 | $49.4K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 39,047 | $69.9K | 0.00% | −85,923−68.8% | Reduced |
| Geode Capital Management, LLC | 131,203 | $234.0K | 0.00% | +2,357+1.8% | Added |
| Bridgeway Capital Management, LLC | 132,700 | $237.5K | 0.01% | 00.0% | Unchanged |
| Vanguard Group Inc | 405,755 | $726.3K | 0.00% | +294+0.1% | Added |
| FMR LLC | 737,596 | $1.32M | 0.00% | −161,803−18.0% | Reduced |
| Sands Capital Ventures, LLC | 811,737 | $1.45M | 0.40% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,125,000 | $2.01M | 0.00% | 00.0% | Unchanged |
| Northpond Ventures, LLC | 1,935,215 | $3.46M | 1.88% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −403,131−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −16,851−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −14,844−100.0% | Sold out |
| Kestra Advisory Services, LLC | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −410−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −271−100.0% | Sold out |